MBOT

Business Context and Reporting Period

Company: StemCells, Inc. (Note: Metadata listed "Microbot Medical Inc." but the filing text identifies the registrant as StemCells, Inc.)
Reporting Period: Quarter and six months ended June 30, 2002.
Business Overview: The company focuses on research and development of human therapeutic products using stem cell technology. It has not commercialized any products and expects to incur substantial operating losses until product sales begin. Operations are funded by cash reserves, equity/debt offerings, and government grants.

Key Financial Metrics

Note: 2001 results included a one-time gain of $7.78 million from the sale of Modex Therapeutics shares, which significantly impacted net income and cash flow for that period.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately 41% year-over-year. This is primarily due to the absence of $300,000 in revenue from the assignment of technology rights recorded in the prior year. Grant revenue increased slightly to $199,549 from $100,000.
• Operating Expenses: Research and Development (R&D) expenses decreased by 19% ($851,000) to $3.65 million, largely due to lower stock option valuation costs, despite an increase in R&D personnel from 24 to 32 employees. General and Administrative (G&A) expenses increased by 14% ($294,000) to $2.39 million, driven by the inclusion of Rhode Island facility costs previously booked against a wind-down reserve.
• Net Income to Loss: The company swung from a net income of $1.86 million in the prior year to a net loss of $5.87 million. The prior year income was heavily influenced by the $7.78 million gain on the sale of Modex shares, which did not recur.
• Liquidity: Cash and cash equivalents decreased by approximately $5.9 million during the six-month period, reducing the cash balance from $13.7 million to $7.8 million.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing capital resources to fund operations through December 2002. The company relies on an equity line of credit (up to $30 million, with $4 million drawn) and potential future financing.
• Facility Risks: The company faces significant ongoing costs (~$1 million net for 2002) for former facilities in Lincoln, Rhode Island. While subleasing efforts are underway, the subtenant for the cell processing facility has entered receivership, creating uncertainty regarding rental income. Failure to sublease or sell these properties could materially adversely affect liquidity.
• Financing Needs: The company must obtain significant additional capital to sustain product development, clinical trials, and regulatory approvals. There is no assurance that financing will be available on acceptable terms.
• Deemed Dividends: The company recorded $640,002 in deemed dividends for the six months ended June 30, 2002, related to the accretion of beneficial conversion features on its 3% Cumulative Convertible Preferred Stock.

Investor Verification Checklist

• Cash Runway: Verify if the $7.8 million cash balance is sufficient to meet the projected burn rate through December 2002, considering the uncertainty of Rhode Island facility sublease income.
• Equity Line Availability: Confirm the remaining capacity and current market conditions affecting the ability to draw down on the $30 million equity line with Sativum Investments Limited.
• Rhode Island Liability: Assess the risk of the cell processing facility subtenant's receivership and the potential for increased costs if the remaining facilities cannot be subleased or sold.
• Preferred Stock Obligations: Review the terms of the 3% and 6% Cumulative Convertible Preferred Stock, specifically the mandatory redemption dates (Dec 2003 and Oct 2002, respectively) and the impact of deemed dividends on common shareholders.
• Grant Sustainability: Evaluate the dependency on NIH grants ($300k/year and $225k/year) which are subject to fund availability and satisfactory project progress.